In a long-awaited trial, Roche’s Alzheimer’s medicine falls short of its objective
A high-stakes race to introduce a treatment for the memory-robbing disease has rivals Biogen (BIIB.O) and Eisai (4523.T) leading the pack after Roche’s (ROG.S) Alzheimer’s medication prototype failed to show potential in two drug studies for slowing dementia progression.In a statement released on Monday, Roche claimed that the twin research findings known as Graduate 1 […]